Acquisition Synergy Serametrix is now part of Caprion Biosciences, creating an expanded immune monitoring and biomarker capabilities platform. This presents cross-sell opportunities to Caprion’s existing pharma clients seeking integrated services from discovery through biomarker validation and large-scale clinical trial support.

Immune Monitoring Focus Strong specialization in measuring immune responses to immunotherapies and analyzing biomarkers linked to drug response and disease progression. Sales outreach can target oncology firms developing IO therapies and companion diagnostic programs seeking robust, validated assays and data analysis.

Global Footprint Global accredited facilities across the Americas, Europe and China enable multinational trial support and rapid assay deployment. Highlight readiness for global clinical programs and local compliance to prospective clients with regional trial needs.

MDSC Expertise Proven know-how in analyzing myeloid-derived suppressor cells in collaboration with major cancer centers. This niche capability can be positioned to sponsors facing resistance to IO therapies and seeking biomarkers to stratify patients or monitor response.

Growth Potential Historical revenue in the low-to-mid millions with a scalable service model and integration with Caprion’s larger portfolio. Target mid-to-large biotechs and mid-sized pharma with ongoing immunotherapy programs that require scalable, validated biomarker services.